Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE vs BUNAVAIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.
Treatment of opioid dependence (buprenorphine/naloxone combination),Management of moderate to severe pain (buprenorphine transdermal or buccal formulations)
FDA-approved for the treatment of opioid dependence, including induction and maintenance therapy.
Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.
For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.
Terminal elimination half-life is 20-73 hours (mean ~37 hours); prolonged half-life supports sublingual dosing every 24-48 hours in opioid dependence.
Terminal elimination half-life of buprenorphine is approximately 24-42 hours (mean ~37 hours) due to slow dissociation from mu-opioid receptors, supporting extended dosing intervals.
Primarily metabolized by CYP3A4 to norbuprenorphine; also glucuronidated by UGT1A1, UGT2B7.
Buprenorphine is primarily metabolized via N-dealkylation by CYP3A4 to norbuprenorphine; also undergoes glucuronidation. Naloxone undergoes hepatic metabolism primarily by glucuronidation.
Primarily fecal (70%) via biliary excretion; renal excretion accounts for 20-30% as unchanged drug and metabolites (mainly norbuprenorphine glucuronide).
Fecal (~70%) as unconjugated buprenorphine and metabolites; renal (~30%) primarily as conjugated metabolites.
96% bound primarily to alpha- and beta-globulins, with negligible binding to albumin.
Approximately 96% bound to alpha- and beta-globulins, not significantly to albumin.
2.5 L/kg (range 1.5-5 L/kg); high Vd indicates extensive tissue distribution (e.g., brain, adipose).
Vd: 2.5-4.0 L/kg, indicating extensive tissue distribution and high lipophilicity.
Sublingual: 30-50% (range 15-55%); buccal: 30-50%; oral: <10% due to extensive first-pass metabolism; intramuscular: 90-100%; intravenous: 100%.
Buccal: ~30-40% relative to intravenous; sublingual: ~30% due to first-pass metabolism; buccal route avoids some gastrointestinal degradation.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution and consider reducing dose or extending interval. Not dialyzable.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl < 30 m L/min): use with caution; consider dose reduction or extended intervals due to potential accumulation of buprenorphine.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce starting dose by 50% (e.g., sublingual 4 mg). Child-Pugh C: Avoid use or reduce dose by 75% (e.g., sublingual 2 mg).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce starting dose by 50% and titrate slowly. For mild impairment (Child-Pugh class A): no dose adjustment required.
Not approved for <16 years. For induction in adolescents: Sublingual 2-4 mg initially, titrated based on response. Maximum 24 mg/day.
Not approved for patients under 16 years; safety and efficacy not established. For adolescents 16 years and older: use adult dosing based on weight and severity.
Reduce initial dose by 25-50% due to increased sensitivity. Titrate slowly. Monitor for respiratory depression and CNS effects.
No specific dose adjustment in elderly; use caution due to increased sensitivity, impaired hepatic/renal function, and risk of falls. Start at low end of dosing range and titrate slowly.
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; WARNING: RISK OF NEONATAL OPIOID WITHDRAWAL SYNDROME
Risk of addiction, abuse, and misuse; respiratory depression and death with IV administration; neonatal opioid withdrawal syndrome with prolonged use; risk of opioid withdrawal with abrupt discontinuation; risk of hepatitis, hepatic events; precipitation of withdrawal if given to patients dependent on full agonists.
Respiratory depression (especially with benzodiazepines or other CNS depressants), neonatal opioid withdrawal syndrome during prolonged use in pregnancy, risk of hepatitis or hepatic injury, adrenal insufficiency, hypotension, QT prolongation, opioid-induced hyperalgesia, risk of withdrawal with partial agonist, misuse potential.
Respiratory depression; neonatal opioid withdrawal syndrome; hepatic injury; precipitation of opioid withdrawal; risks from concomitant use with benzodiazepines or CNS depressants; dependence and withdrawal; use in patients with compromised respiratory function; increased intracranial pressure; hypotension; biliary tract disease; QT prolongation; impairment of driving/operating machinery.
Hypersensitivity to buprenorphine, severe respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (including paralytic ileus), concomitant use with full mu-opioid agonists (risk of precipitated withdrawal).
Hypersensitivity to buprenorphine or naloxone; patients with significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; patients not already dependent on opioids (for induction).
No significant food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition; concurrent use is not recommended. Avoid excessive alcohol consumption.
No significant food interactions. However, patients should avoid grapefruit juice as it may increase buprenorphine levels. Advise to take on an empty stomach for consistent absorption, though food does not significantly alter bioavailability.
FDA Pregnancy Category C. First trimester: No increased risk of major malformations based on human data, but animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) requiring monitoring. Use only if benefit outweighs risk.
Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Use in pregnancy only if benefit outweighs risk.
Buprenorphine is excreted in breast milk with a relative infant dose of 1-2% of maternal weight-adjusted dose. M/P ratio approximately 1.0 based on limited data. The American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for sedation, feeding difficulties, and withdrawal if breastfeeding is abruptly stopped.
Buprenorphine is excreted into breast milk in low concentrations; estimated relative infant dose is 2.4% of maternal weight-adjusted dose. M/P ratio is not well established. Caution is advised, monitor for infant sedation and respiratory depression.
No routine dose adjustment required in pregnancy due to minimal pharmacokinetic changes. However, increased clearance in third trimester may necessitate dose increase (typically 2-4 mg/day) to maintain therapeutic effect. Taper to avoid withdrawal prior to delivery is not recommended due to risk of preterm labor and fetal distress.
Pregnancy may alter buprenorphine pharmacokinetics; dose adjustments may be needed to avoid withdrawal or oversedation. Monitor clinical response and adjust doses in increments of 2-4 mg sublingual buprenorphine as needed, guided by withdrawal symptoms and cravings.
Buprenorphine is a partial mu-opioid agonist; its ceiling effect reduces respiratory depression risk but may precipitate withdrawal in opioid-dependent patients if administered too soon after full agonists. Sublingual tablets require adequate dissolution under the tongue for 5-10 minutes; advise patient not to swallow or talk during dissolution. Naloxone is combined to deter intravenous misuse; sublingual bioavailability of naloxone is low, but intravenous injection can precipitate withdrawal. Avoid use in patients with severe hepatic impairment due to extensive first-pass metabolism. Monitor for QT prolongation, especially at high doses or with concomitant QT-prolonging drugs.
BUNAVAIL (buprenorphine/naloxone) sublingual film is indicated for maintenance treatment of opioid dependence. Administer as a single daily dose; films can be cut to achieve lower doses. Avoid abrupt discontinuation to prevent withdrawal. Monitor for respiratory depression, especially during induction. Use with caution in patients with hepatic impairment; naloxone component may precipitate withdrawal in opioid-tolerant patients if injected.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or sedatives (benzodiazepines, other opioids) while taking this medication, as it may cause severe drowsiness, respiratory depression, or coma.,Do not drive or operate machinery until you know how buprenorphine affects you; dizziness or drowsiness may occur.,If you miss a dose, take it as soon as remembered; if close to next dose, skip the missed dose and resume normal schedule. Do not double doses.,Store at room temperature away from moisture and heat; keep out of reach of children.,Do not stop abruptly; abrupt discontinuation may cause withdrawal symptoms. Your doctor will taper your dose gradually.,If you experience signs of allergic reaction (rash, hives, swelling, difficulty breathing) or signs of overdose (slow/shallow breathing, severe drowsiness, pinpoint pupils), seek emergency medical attention.,Inform all healthcare providers that you are taking buprenorphine; carry a medication card or alert bracelet.
Place the film under the tongue and allow it to dissolve completely; do not chew, swallow, or move the film after placement.,Do not drink or eat until the film has completely dissolved.,Avoid use of alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication as it may increase risk of respiratory depression.,Do not stop taking this medication suddenly without consulting your healthcare provider as withdrawal symptoms may occur.,Store at room temperature away from moisture and heat; keep out of reach of children.,This medication can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Inform all healthcare providers that you are taking this medication before any surgery or emergency treatment.,Do not take other opioids, including illicit drugs, while on this medication as it may cause severe withdrawal or overdose.
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE vs BUNAVAIL, answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors, producing analgesia and reducing opioid withdrawal symptoms.. BUNAVAIL is a Opioid Partial Agonist Combination that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE and BUNAVAIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE is: Sublingual: 8-16 mg once daily. Transdermal: 5-20 mcg/hour applied every 7 days. Injectable: 0.3 mg IM/IV every 6-8 hours as needed.. The standard adult dose of BUNAVAIL is: For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE HYDROCHLORIDE and BUNAVAIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. First trimester: No increased risk of major malformations based on human data, but animal studies show increased fetal loss and skeletal abnormalities at . BUNAVAIL is classified as Category C. Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.